Top Qs
Timeline
Chat
Perspective
Sipavibart
Medication From Wikipedia, the free encyclopedia
Remove ads
Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised.[3] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.[3][5]
Sipavibart was authorized for medical use in the European Union in January 2025.[3][4]
Remove ads
Medical uses
Sipavibart is indicated for the pre-exposure prophylaxis of COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments.[3][4]
Society and culture
Legal status
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID-19 in immunocompromised people aged twelve years of age and older.[3] Kavigale was reviewed under the EMA's accelerated assessment program.[3] The applicant for this medicinal product is AstraZeneca AB.[3] Sipavibart was authorized for medical use in the European Union in January 2025.[3][4]
Names
Sipavibart is the international nonproprietary name.[6]
Remove ads
References
Further reading
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads